End-of-day quote
Shenzhen S.E.
03:30:00 27/06/2024 am IST
|
5-day change
|
1st Jan Change
|
5.3
CNY
|
-3.81%
|
|
-4.50%
|
-39.50%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
2,662
|
1,491
|
1,961
|
1,955
|
2,577
|
2,680
|
Enterprise Value (EV)
1 |
2,324
|
1,149
|
1,602
|
1,629
|
2,292
|
2,310
|
P/E ratio
|
56.9
x
|
42
x
|
50.3
x
|
43.2
x
|
45.3
x
|
44.8
x
|
Yield
|
0.36%
|
0.49%
|
0.42%
|
0.45%
|
0.66%
|
0.67%
|
Capitalization / Revenue
|
9.31
x
|
5.06
x
|
6.02
x
|
6.12
x
|
6.78
x
|
6.26
x
|
EV / Revenue
|
8.13
x
|
3.9
x
|
4.92
x
|
5.1
x
|
6.03
x
|
5.39
x
|
EV / EBITDA
|
37.4
x
|
22.6
x
|
28.2
x
|
26.2
x
|
29
x
|
26.8
x
|
EV / FCF
|
596
x
|
-493
x
|
217
x
|
-59.5
x
|
-47.3
x
|
106
x
|
FCF Yield
|
0.17%
|
-0.2%
|
0.46%
|
-1.68%
|
-2.11%
|
0.94%
|
Price to Book
|
4
x
|
2.15
x
|
2.71
x
|
2.57
x
|
3.18
x
|
3.14
x
|
Nbr of stocks (in thousands)
|
2,99,098
|
2,99,098
|
2,99,098
|
2,99,098
|
2,99,098
|
2,99,098
|
Reference price
2 |
8.899
|
4.984
|
6.558
|
6.537
|
8.614
|
8.960
|
Announcement Date
|
20/04/18
|
25/04/19
|
24/04/20
|
27/04/21
|
10/03/22
|
27/04/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
286
|
294.7
|
325.6
|
319.4
|
379.9
|
428.3
|
EBITDA
1 |
62.09
|
50.79
|
56.8
|
62.24
|
79.05
|
86.2
|
EBIT
1 |
38.4
|
25.86
|
28.11
|
33
|
45.76
|
43.77
|
Operating Margin
|
13.43%
|
8.78%
|
8.63%
|
10.33%
|
12.04%
|
10.22%
|
Earnings before Tax (EBT)
1 |
53.88
|
39.46
|
42.79
|
49.57
|
61.86
|
60.87
|
Net income
1 |
46.42
|
35.97
|
39.13
|
45.26
|
56.89
|
60.85
|
Net margin
|
16.23%
|
12.2%
|
12.02%
|
14.17%
|
14.97%
|
14.21%
|
EPS
2 |
0.1565
|
0.1188
|
0.1304
|
0.1513
|
0.1902
|
0.2000
|
Free Cash Flow
1 |
3.9
|
-2.33
|
7.385
|
-27.4
|
-48.48
|
21.73
|
FCF margin
|
1.36%
|
-0.79%
|
2.27%
|
-8.58%
|
-12.76%
|
5.07%
|
FCF Conversion (EBITDA)
|
6.28%
|
-
|
13%
|
-
|
-
|
25.21%
|
FCF Conversion (Net income)
|
8.4%
|
-
|
18.87%
|
-
|
-
|
35.72%
|
Dividend per Share
2 |
0.0319
|
0.0246
|
0.0275
|
0.0296
|
0.0571
|
0.0600
|
Announcement Date
|
20/04/18
|
25/04/19
|
24/04/20
|
27/04/21
|
10/03/22
|
27/04/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
338
|
342
|
359
|
326
|
284
|
370
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
3.9
|
-2.33
|
7.38
|
-27.4
|
-48.5
|
21.7
|
ROE (net income / shareholders' equity)
|
7.16%
|
5%
|
5.12%
|
5.85%
|
7.06%
|
7.33%
|
ROA (Net income/ Total Assets)
|
3.34%
|
2.13%
|
2.18%
|
2.36%
|
2.9%
|
2.62%
|
Assets
1 |
1,391
|
1,690
|
1,795
|
1,918
|
1,959
|
2,326
|
Book Value Per Share
2 |
2.230
|
2.320
|
2.420
|
2.550
|
2.710
|
2.850
|
Cash Flow per Share
2 |
0.8300
|
1.140
|
0.6900
|
0.8100
|
1.150
|
1.070
|
Capex
1 |
27.5
|
33.2
|
24.7
|
93.8
|
75.8
|
34.1
|
Capex / Sales
|
9.61%
|
11.28%
|
7.59%
|
29.36%
|
19.96%
|
7.97%
|
Announcement Date
|
20/04/18
|
25/04/19
|
24/04/20
|
27/04/21
|
10/03/22
|
27/04/23
|
|
1st Jan change
|
Capi.
|
---|
| -39.50% | 227M | | +54.91% | 811B | | +43.62% | 640B | | -7.16% | 353B | | +17.85% | 333B | | +8.62% | 302B | | +16.30% | 246B | | +2.41% | 225B | | +12.47% | 218B | | +8.57% | 168B |
Other Pharmaceuticals
|